This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
by Zacks Equity Research
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
Geron (GERN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -33.33% and -49.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Geron (GERN) Down 22% Since Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron Stock Up More Than 50% in 2019 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Geron (GERN) Up 27.3% Since Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up
by Zacks Equity Research
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Geron (GERN) Down 13% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Geron (GERN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 40.00% and -25.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
Geron (GERN) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Geron (GERN) closed at $1.72, marking a -0.58% move from the previous day.
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
Geron's Stock Plunges as J&J Ends Imetelstat Collaboration
by Zacks Equity Research
Geron (GERN) announces termination of collaboration with J&J for development of its sole pipeline candidate, imetelstat.
Options Traders Expect Huge Moves in Geron (GERN) Stock
by Zacks Equity Research
Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.
Geron Stock Up More Than 200% in 2018 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.
Why Is Geron (GERN) Up 58% Since Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron's Growth Depends on Continuation of Imetelstat Studies
by Zacks Equity Research
Investors continue to focus on development of Geron's (GERN) sole pipeline candidate, imetelstat. However, competition is rife with other companies developing treatments for similar indications.
Implied Volatility Surging for Geron (GERN) Stock Options
by Zacks Equity Research
Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.